Multiple SclerosisVIRTUENCT07096700
VR and Orthoses for Rehabilitation in Multiple Sclerosis
A study testing VR and walking brace-based gait rehabilitation in people with Multiple Sclerosis, run by Azienda Usl di Bologna at 2 sites in Italy.
Trial summary
This non-drug, non-medical device, interventional study explores the feasibility of integrating virtual reality (VR) with wearable sensors to support gait training using a passive orthosis in individuals with multiple sclerosis (MS). Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Multiple Sclerosis
- What is being tested?
- VR and walking brace-based gait rehabilitation
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 12 participants
- Where
- 2 sitesItaly
- Study dates
- 2 Mar 2026to Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Confirmed diagnosis of multiple sclerosis
- Age between 18 and 65 years
- Both sexes
- Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS > 100)
- Expanded Disability Status Scale (EDSS between 3 and 6 inclusive)
- Berg Balance Scale (BBS ≥ 46)
Show all 9Show fewer
- Indication for the use of the Exoband orthosis for gait assistance
- Modified Fatigue Impact Scale (MFIS) physical subscale ≤ 20
- Signed informed consent
Who cannot join
- Presence of severe or current visual or auditory impairments
- Relapses within the last 3 months
- Presence of severe anxiety or depression
- Severe spasticity patterns in the lower limbs or fixed distal tendon contractures
- Presence of motion sickness symptoms induced by virtual reality (VR)
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Italy2 sites, 2 recruiting
- Not yet recruiting
IRCCS Istituto delle Scienze Neurologiche di Bologna - AUSL of Bologna
Bologna, Bologna, 40139
Kevin Marcaccini, +390514966403, kevin.marcaccini@ausl.bologna.it
Loredana Sabattini, +3905174966217, loredana.sabattini@isnb.it
- Recruiting
IRCCS Istituto delle Scienze Neurologiche di Bologna - AUSL of Bologna
Bologna, BO, 40139
Kevin Marcaccini, +390514966403, kevin.marcaccini@ausl.bologna.it
About this study
Official title: Virtual Reality for Gait Training in Multiple Sclerosis (VIRTUE): an Interventional Feasibility Study
This non-drug, non-medical device, interventional study explores the feasibility of integrating virtual reality (VR) with wearable sensors to support gait training using a passive orthosis in individuals with multiple sclerosis (MS). The aim is to determine whether this approach can enhance clinical gait assessment and facilitate orthosis adaptation by replicating real-life scenarios within a safe and controlled environment. The virtual environment, accessed through a head-mounted display, will be delivered via a custom simulator incorporating standardized gait tasks embedded in everyday settings. This system is designed to minimize the artificial influence of clinical settings on walking performance, while providing clinicians with objective gait data for more comprehensive evaluation.
Read the detailed description
Patients with multiple sclerosis (MS) often experience significant gait impairments that impact their autonomy and overall quality of life. One of the primary rehabilitation strategies involves the use of walking braces. While these orthotic devices can support ambulation, their effective integration into daily life typically requires a period of adaptation and specific training. Traditionally, gait training and orthosis prescription occur in clinical settings, which may not fully reflect the real-world challenges that patients encounter. Moreover, current clinical assessments rely primarily on subjective observations and standardized scales, which may lack the sensitivity and objectivity needed to capture the full complexity of gait performance.
virtual reality (VR) offers a promising opportunity to simulate realistic walking environments in a controlled and safe setting, such as an outpatient clinic, potentially enhancing the outcomes of gait rehabilitation. Another promising technology in this domain is the use of wearable inertial sensors, which have been shown to effectively measure gait and postural parameters in people with MS. A further challenge associated with the use of orthotic devices is the physical and psychological stress they may cause, which can lead patients to discontinue their use. To evaluate such discomfort more objectively, recent studies have explored the use of physiological signal analysis and machine learning (ML) algorithms as an alternative or complement to self-reported questionnaires.
The integration of VR with wearable inertial and physiological sensors may allow for a more comprehensive and objective assessment of a patient's adaptation to walking braces. However, no validated system currently exists that combines these technologies for gait assessment and training with passive orthoses in people with MS.
The VIRTUE study aims to address this gap by developing and evaluating a VR-based platform (VIRTUE4MS) that replicates real-life scenarios, such as navigating through a museum, park, or grocery store, and enables standardized gait assessments within immersive environments. The system will employ both inertial and physiological wearable sensors to gather data on gait dynamics and user experience, ultimately supporting clinical decision-making regarding orthotic use. In this study, 12 patients with MS will perform walking and balance tasks over three sessions (T1, T2, T3), both with and without the Exoband brace, in VR and real-world conditions. Ultimately, this study seeks to explore an innovative, technology-supported approach to orthosis assessment and gait training that could complement traditional clinical tools and contribute to more effective, personalized rehabilitation strategies for individuals with MS.
- Conditions
- Multiple Sclerosis
- Being tested
- VR and walking brace-based gait rehabilitation
- Keywords
- Multiple sclerosis, Neurorehabilitation, Gait impairments, Virtual Reality, Wearable technology, Sensor-based monitoring, Inertial sensors, Physiological signals, Walking braces, Remote monitoring
- Medical subject headings
- Multiple Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VR and walking brace-based gait rehabilitationOther
The study implements the use of VR and wearable sensors to enhance gait analysis in clinical practice. Participants will take part in two outpatient sessions (T1 and T2) involving the use of VR and wearable sensors, during which they will be asked to complete standardized gait tests and questionnaires. These two sessions will be separated by a one-week home phase (Th), during which participants will wear the walking brace in their daily activities and their gait and physiological data will be recorded by wearable sensors. A final session (T3), conducted without VR, will be scheduled two months later to assess the long-term retention of the intervention effects.
| Study group | Role | What they receive |
|---|---|---|
| VR - Multiple Sclerosis | Other | Twelve adults with multiple sclerosis who require a walking brace to support ambulation and are compatible with Virtual Reality Receives: Other: VR and walking brace-based gait rehabilitation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Score of the standardized tests and gait parameters
This outcome assesses the adaptation to the walking brace during ambulation. Gait performance across different sessions will be analyzed and compared to observe improvement between T1 and T2. Participant satisfaction with the use of VR will be considered met if individuals can successfully engage with and complete the sessions using the system.
Measured: From T1 (day 2) to T2 (day 9)
Secondary outcomes (13)
NASA-TLX (NASA Task Load Index) questionnaire score
The NASA-TLX questionnaire score (National Aeronautics and Space Administration Task Load Index) measures physical and mental workload using six items related to mental load, physical activity, speed of performance, performance, effort, and frustration. Each item is accompanied by a 12 cm line scale divided into 20 equal intervals, anchored by binary descriptors (e.g., low/high), delimited by 21 vertical markers, and then converted to a scale from 0 to 100 points. To calculate the score for each scale, the number of lines marked by a participant is counted, 1 is subtracted, and the result is multiplied by 5. Weights from 0-5 will be assigned to the 15 subscale comparisons, which will be multiplied by the corresponding subscale score. The total score (from 0 to 100 points) is estimated by summing the weighted scores and dividing by 15.
Measured: T1 (day 2); T2 (day 10); T3 (day 70)
MSAQ (Motion Sickness Assessment Questionnaire) questionnaire score
The MSAQ questionnaire assesses motion sickness. It consists of 16 questions divided into four subcategories: Gastrointestinal (G), Central (C), Peripheral (P), and Sopite-related (S). Responses are scored on a scale from 1 to 9 points. Each subcategory is scored individually, contributing to a total score ranging from 11 to 144 points. The overall motion sickness score is calculated as the percentage of total points scored: (sum of all item points / 144) × 100. Subscale scores are calculated similarly as percentages within each factor: (sum of gastrointestinal items / 36) × 100; (sum of central items / 45) × 100; (sum of peripheral items / 27) × 100; (sum of sopite items / 36) × 100.
Measured: T0 (day 1); T1 (day 2); T2 (day 10)
IPQ (iGroupPresence Questionnaire) questionnaire score
The IPQ questionnaire assesses the sense of presence (SOP - level of immersion in VR) of a VR user. The IPQ consists of 14 items divided into four subcategories: spatial presence, involvement, perceived realism level, and a "sense of being present." All items are rated on a seven-point scale (0-6), with a higher score indicating greater SOP. The total score is obtained by summing the scores of individual items (from 0 to 84 points).
Measured: T1 (day 2); T2 (day 10)
MusiQoL (Multiple Sclerosis International Quality of Life) questionnaire score
The MusiQoL questionnaire assesses health-related quality of life specifically in individuals with multiple sclerosis. It consists of 31 items grouped into nine dimensions: daily activities, psychological well-being, symptoms, social relationships, family relationships, relationship with healthcare professionals, emotional well-being, intimate relationships, and leisure activities. Each item is rated on a five-point Likert scale (from 1 = "never" to 5 = "always"). Scores for each dimension are calculated as the mean of the corresponding items, then transformed into a 0-100 scale, with higher scores indicating better quality of life.
Measured: T1 (day 2), T2 (day 10), T3 (day 70)
BBS (Berg Balance Scale) questionnaire score
The BBS is a clinical assessment tool used to evaluate balance and fall risk in individuals. It consists of 14 functional tasks, each scored on a scale from 0 (unable to perform) to 4 (normal performance), with a maximum total score of 56 points. The items assess the ability to maintain upright standing positions without support (eyes open, closed, feet together, tandem, single-leg stance), perform posture transitions (e.g., sitting to standing, transfers between bed and chair), turn the body, and complete other tasks requiring static and dynamic postural control.
Measured: T1 (day 2); T2 (day 10); T3 (day 70)
EDSS (Expanded Disability Status Scale) questionnaire score
The EDSS is an ordinal rating scale used to quantify disability in individuals with multiple sclerosis. Scores range from 0 (normal neurological status) to 10 (death due to MS), with 0.5-point increments indicating increasing levels of disability. The scale evaluates several functional systems, including motor, sensory, visual, bowel and bladder functions, and cognitive impairments, providing an overall measure of disability.
Measured: T0 (day 1)
MFIS (Modified Fatigue Impact Scale) questionnaire score
The MFIS is a 21-item self-report questionnaire that assesses the perceived impact of fatigue on daily life, covering three domains: physical (0-36), cognitive (0-40), and psychosocial (0-8). Each item is rated from 0 to 4. The total score ranges from 0 to 84, with higher scores indicating greater fatigue impact. Subscale scores provide domain-specific insights, useful for monitoring targeted therapeutic interventions.
Measured: T0 (day 1); T1 (day 2); Th (day 3-9); T2 (day 10); T3 (day 70)
MSWS-12 (Twelve-Item Multiple Sclerosis Walking Scale) questionnaire score
The MSWS-12 is a self-reported questionnaire designed to measure the impact of MS on walking ability. It consists of 12 items rated on a 5-point scale (1-5), reflecting perceived walking difficulties over the past two weeks. Assessed domains include balance, speed, walking distance, and need for assistance. The total raw score is converted to a 0-100 scale, with higher scores indicating greater walking disability.
Measured: T1 (day 2); T2 (day 10); T3 (day 70)
Timed 25-Foot Walk Test (T25FW) test score
The T25FW assesses walking speed and is used to evaluate the walking ability of individuals with multiple sclerosis. The test involves the participant walking 25 feet (approximately 7.62 meters) as quickly as possible, performing two separate trials. The time taken to complete each trial is measured in seconds using a stopwatch. The final score is calculated by averaging the two recorded times.
Measured: T1 (day 2); T2 (day 10); T3 (day 70)
2MWT (2-Minute Walk Test) test score
The 2MWT is a test used to assess walking ability, in which the subject is asked to walk as fast as possible for 2 minutes on a flat surface. The total distance covered during this time is measured. The test evaluates walking speed, as well as the patient's cardiovascular and muscular endurance.
Measured: T1 (day 2); T2 (day 10); T3 (day 70)
TAM (Technology Acceptance Model) questionnaire score
The TAM is a tool used to measure users' acceptance of technology, based on two key components: perceived usefulness (how much the user believes the technology improves their performance) and perceived ease of use (how easy the user finds the technology to use). The test includes 12 items scored from 1 to 4, with a total score of 48. Higher scores indicate lower acceptance of the technology.
Measured: T0 (day 1); T2 (day 10)
TLSQ-WT (Tele-healthcare Satisfaction Questionnaire - Wearable Technology) questionnaire score
The TLSQ-WT is an assessment tool designed to measure patients' satisfaction with telemedicine services. It evaluates six dimensions of the user experience with the wearable component of a system: Benefits, Usability, Self-perception, Privacy and Loss of Control, Quality of Life, and Comfort of Use.
Each area includes five statements rated by the user on a 5-point Likert scale from 0 (strongly disagree) to 4 (strongly agree), for a total of 30 items. The final score ranges from 0 to 120.
Measured: T2 (day 10)
Timed Up and Go (TUG) test score
The TUG (Podsiadlo \& Richardson, 1991) is a functional test commonly used to assess mobility and fall risk in patients with neurological conditions, including multiple sclerosis. The test involves asking the patient to stand up from a chair, walk 3 meters, turn around, walk back, and sit down again. The time required to complete the task is recorded in seconds using a stopwatch.
Measured: T1 (day 2); T2 (day 10); T3 (day 70)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jul 2025
- Study start2 Mar 2026
- Primary completionJun 2026 (estimated)
- Study completionSep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 12 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Azienda Usl di Bologna
- Sponsor type
- Other government
- Responsible party
- Sponsor
- Investigators
- Loredana Sabattini, Principal investigator, IRCCS Istituto delle Scienze Neurologiche di Bologna - AUSL of Bologna
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07096700
- Sponsor's protocol ID
- VIRTUE
- Acronym
- VIRTUE
- Status last verified
- Mar 2026
- First submitted
- 24 Jul 2025
- Last updated
- 30 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Tsai MF, Bandini A, Wang RH, Zariffa J. Capturing Representative Hand Use at Home Using Egocentric Video in Individuals with Upper Limb Impairment. J Vis Exp. 2020 Dec 23;(166). doi: 10.3791/61898.
PubMed 33427235Casuso-Holgado MJ, Martin-Valero R, Carazo AF, Medrano-Sanchez EM, Cortes-Vega MD, Montero-Bancalero FJ. Effectiveness of virtual reality training for balance and gait rehabilitation in people with multiple sclerosis: a systematic review and meta-analysis. Clin Rehabil. 2018 Sep;32(9):1220-1234. doi: 10.1177/0269215518768084. Epub 2018 Apr 13.
PubMed 29651873Peruzzi A, Cereatti A, Della Croce U, Mirelman A. Effects of a virtual reality and treadmill training on gait of subjects with multiple sclerosis: a pilot study. Mult Scler Relat Disord. 2016 Jan;5:91-6. doi: 10.1016/j.msard.2015.11.002. Epub 2015 Nov 6.
PubMed 26856951Bettoni E, Ferriero G, Bakhsh H, Bravini E, Massazza G, Franchignoni F. A systematic review of questionnaires to assess patient satisfaction with limb orthoses. Prosthet Orthot Int. 2016 Apr;40(2):158-69. doi: 10.1177/0309364614556836. Epub 2014 Nov 26.
PubMed 25428901Marimon X, Mengual I, Lopez-de-Celis C, Portela A, Rodriguez-Sanz J, Herraez IA, Perez-Bellmunt A. Kinematic Analysis of Human Gait in Healthy Young Adults Using IMU Sensors: Exploring Relevant Machine Learning Features for Clinical Applications. Bioengineering (Basel). 2024 Jan 23;11(2):105. doi: 10.3390/bioengineering11020105.
PubMed 38391591Panizzolo FA, Cimino S, Pettenello E, Belfiore A, Petrone N, Marcolin G. Effect of a passive hip exoskeleton on walking distance in neurological patients. Assist Technol. 2022 Sep 3;34(5):527-532. doi: 10.1080/10400435.2021.1880494. Epub 2021 Mar 5.
PubMed 33481693Karunakaran KK, Pamula SD, Bach CP, Legelen E, Saleh S, Nolan KJ. Lower extremity robotic exoskeleton devices for overground ambulation recovery in acquired brain injury-A review. Front Neurorobot. 2023 May 25;17:1014616. doi: 10.3389/fnbot.2023.1014616. eCollection 2023.
PubMed 37304666Homayuni A, Abedini S, Hosseini Z, Etemadifar M, Ghanbarnejad A. Explaining the facilitators of quality of life in patients with multiple sclerosis: a qualitative study. BMC Neurol. 2021 May 11;21(1):193. doi: 10.1186/s12883-021-02213-9.
PubMed 33975555Gil-Gonzalez I, Martin-Rodriguez A, Conrad R, Perez-San-Gregorio MA. Quality of life in adults with multiple sclerosis: a systematic review. BMJ Open. 2020 Nov 30;10(11):e041249. doi: 10.1136/bmjopen-2020-041249.
PubMed 33257490Marcaccini K, Aleo A, Pozzi S, Sgambato G, Chiari L, Verrengia MG, Milano DC, Moscato S, Mellone S, Arcobelli VA, Sabattini L, Orlandi S. Interventional Feasibility Study Investigating Virtual Reality-Based Gait Assessment With Orthoses in People With Multiple Sclerosis: A Study Protocol. Clin Transl Sci. 2026 Sep;19(9):e70728. doi: 10.1111/cts.70728.
PubMed 42717397
Study at a glance
From the registry record, last updated by the sponsor on 30 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Virtual Reality for Gait Training in Multiple Sclerosis (VIRTUE): an Interventional Feasibility Study
- ClinicalTrials.gov ID
- NCT07096700
- Acronym / sponsor ID
- VIRTUE / VIRTUE
- Conditions
- Multiple Sclerosis
- Keywords
- Multiple sclerosis, Neurorehabilitation, Gait impairments, Virtual Reality, Wearable technology, Sensor-based monitoring, Inertial sensors, Physiological signals
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 12 participants (estimated)
- Lead sponsor
- Azienda Usl di BolognaOther government
- Study start
- 2 Mar 2026 (actual)
- Primary completion
- Jun 2026 (estimated)
- Study completion
- Sep 2026 (estimated)
- First posted
- 31 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This non-drug, non-medical device, interventional study explores the feasibility of integrating virtual reality (VR) with wearable sensors to support gait training using a passive orthosis in individuals with multiple sclerosis (MS). The aim is to determine whether this approach can enhance clinical gait assessment and facilitate orthosis adaptation by replicating real-life scenarios within a safe and controlled environment. The virtual environment, accessed through a head-mounted display, will be delivered via a custom simulator incorporating standardized gait tasks embedded in everyday settings. This system is designed to minimize the artificial influence of clinical settings on walking performance, while providing clinicians with objective gait data for more comprehensive evaluation.
Detailed description
Patients with multiple sclerosis (MS) often experience significant gait impairments that impact their autonomy and overall quality of life. One of the primary rehabilitation strategies involves the use of walking braces. While these orthotic devices can support ambulation, their effective integration into daily life typically requires a period of adaptation and specific training. Traditionally, gait training and orthosis prescription occur in clinical settings, which may not fully reflect the real-world challenges that patients encounter. Moreover, current clinical assessments rely primarily on subjective observations and standardized scales, which may lack the sensitivity and objectivity needed to capture the full complexity of gait performance.
virtual reality (VR) offers a promising opportunity to simulate realistic walking environments in a controlled and safe setting, such as an outpatient clinic, potentially enhancing the outcomes of gait rehabilitation. Another promising technology in this domain is the use of wearable inertial sensors, which have been shown to effectively measure gait and postural parameters in people with MS. A further challenge associated with the use of orthotic devices is the physical and psychological stress they may cause, which can lead patients to discontinue their use. To evaluate such discomfort more objectively, recent studies have explored the use of physiological signal analysis and machine learning (ML) algorithms as an alternative or complement to self-reported questionnaires.
The integration of VR with wearable inertial and physiological sensors may allow for a more comprehensive and objective assessment of a patient's adaptation to walking braces. However, no validated system currently exists that combines these technologies for gait assessment and training with passive orthoses in people with MS.
The VIRTUE study aims to address this gap by developing and evaluating a VR-based platform (VIRTUE4MS) that replicates real-life scenarios, such as navigating through a museum, park, or grocery store, and enables standardized gait assessments within immersive environments. The system will employ both inertial and physiological wearable sensors to gather data on gait dynamics and user experience, ultimately supporting clinical decision-making regarding orthotic use. In this study, 12 patients with MS will perform walking and balance tasks over three sessions (T1, T2, T3), both with and without the Exoband brace, in VR and real-world conditions. Ultimately, this study seeks to explore an innovative, technology-supported approach to orthosis assessment and gait training that could complement traditional clinical tools and contribute to more effective, personalized rehabilitation strategies for individuals with MS.
Study design
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| VR - Multiple Sclerosis | Other | Other: VR and walking brace-based gait rehabilitationTwelve adults with multiple sclerosis who require a walking brace to support ambulation and are compatible with Virtual Reality |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Confirmed diagnosis of multiple sclerosis
- Age between 18 and 65 years
- Both sexes
- Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS > 100)
- Expanded Disability Status Scale (EDSS between 3 and 6 inclusive)
Key exclusion criteria (5 listed)
- Presence of severe or current visual or auditory impairments
- Relapses within the last 3 months
- Presence of severe anxiety or depression
- Severe spasticity patterns in the lower limbs or fixed distal tendon contractures
- Presence of motion sickness symptoms induced by virtual reality (VR)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VR and walking brace-based gait rehabilitationThe study implements the use of VR and wearable sensors to enhance gait analysis in clinical practice. Participants will take part in two outpatient sessions (T1 and T2) involving the use of VR and wearable sensors, during which they will be asked to complete standardized gait tests and questionnaires. These two sessions will be separated by a one-week home phase (Th), during which participants will wear the walking brace in their daily activities and their gait and physiological data will be recorded by wearable sensors. A final session (T3), conducted without VR, will be scheduled two months later to assess the long-term retention of the intervention effects. | Other | VR - Multiple Sclerosis |
Primary outcome
Score of the standardized tests and gait parameters
Time frame: From T1 (day 2) to T2 (day 9)
This outcome assesses the adaptation to the walking brace during ambulation. Gait performance across different sessions will be analyzed and compared to observe improvement between T1 and T2. Participant satisfaction with the use of VR will be considered met if individuals can successfully engage with and complete the sessions using the system.
13 secondary outcomes
NASA-TLX (NASA Task Load Index) questionnaire score
Time frame: T1 (day 2); T2 (day 10); T3 (day 70)
MSAQ (Motion Sickness Assessment Questionnaire) questionnaire score
Time frame: T0 (day 1); T1 (day 2); T2 (day 10)
IPQ (iGroupPresence Questionnaire) questionnaire score
Time frame: T1 (day 2); T2 (day 10)
MusiQoL (Multiple Sclerosis International Quality of Life) questionnaire score
Time frame: T1 (day 2), T2 (day 10), T3 (day 70)
BBS (Berg Balance Scale) questionnaire score
Time frame: T1 (day 2); T2 (day 10); T3 (day 70)
EDSS (Expanded Disability Status Scale) questionnaire score
Time frame: T0 (day 1)
MFIS (Modified Fatigue Impact Scale) questionnaire score
Time frame: T0 (day 1); T1 (day 2); Th (day 3-9); T2 (day 10); T3 (day 70)
MSWS-12 (Twelve-Item Multiple Sclerosis Walking Scale) questionnaire score
Time frame: T1 (day 2); T2 (day 10); T3 (day 70)
Timed 25-Foot Walk Test (T25FW) test score
Time frame: T1 (day 2); T2 (day 10); T3 (day 70)
2MWT (2-Minute Walk Test) test score
Time frame: T1 (day 2); T2 (day 10); T3 (day 70)
TAM (Technology Acceptance Model) questionnaire score
Time frame: T0 (day 1); T2 (day 10)
TLSQ-WT (Tele-healthcare Satisfaction Questionnaire - Wearable Technology) questionnaire score
Time frame: T2 (day 10)
Timed Up and Go (TUG) test score
Time frame: T1 (day 2); T2 (day 10); T3 (day 70)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Mar 2026.
- Background: PubMed 33427235Tsai MF, Bandini A, Wang RH, Zariffa J. Capturing Representative Hand Use at Home Using Egocentric Video in Individuals with Upper Limb Impairment. J Vis Exp. 2020 Dec 23;(166). doi: 10.3791/61898.
- Background: PubMed 29651873Casuso-Holgado MJ, Martin-Valero R, Carazo AF, Medrano-Sanchez EM, Cortes-Vega MD, Montero-Bancalero FJ. Effectiveness of virtual reality training for balance and gait rehabilitation in people with multiple sclerosis: a systematic review and meta-analysis. Clin Rehabil. 2018 Sep;32(9):1220-1234. doi: 10.1177/0269215518768084. Epub 2018 Apr 13.
- Background: PubMed 26856951Peruzzi A, Cereatti A, Della Croce U, Mirelman A. Effects of a virtual reality and treadmill training on gait of subjects with multiple sclerosis: a pilot study. Mult Scler Relat Disord. 2016 Jan;5:91-6. doi: 10.1016/j.msard.2015.11.002. Epub 2015 Nov 6.
- Background: PubMed 25428901Bettoni E, Ferriero G, Bakhsh H, Bravini E, Massazza G, Franchignoni F. A systematic review of questionnaires to assess patient satisfaction with limb orthoses. Prosthet Orthot Int. 2016 Apr;40(2):158-69. doi: 10.1177/0309364614556836. Epub 2014 Nov 26.
- Background: PubMed 38391591Marimon X, Mengual I, Lopez-de-Celis C, Portela A, Rodriguez-Sanz J, Herraez IA, Perez-Bellmunt A. Kinematic Analysis of Human Gait in Healthy Young Adults Using IMU Sensors: Exploring Relevant Machine Learning Features for Clinical Applications. Bioengineering (Basel). 2024 Jan 23;11(2):105. doi: 10.3390/bioengineering11020105.
- Background: PubMed 33481693Panizzolo FA, Cimino S, Pettenello E, Belfiore A, Petrone N, Marcolin G. Effect of a passive hip exoskeleton on walking distance in neurological patients. Assist Technol. 2022 Sep 3;34(5):527-532. doi: 10.1080/10400435.2021.1880494. Epub 2021 Mar 5.
- Background: PubMed 37304666Karunakaran KK, Pamula SD, Bach CP, Legelen E, Saleh S, Nolan KJ. Lower extremity robotic exoskeleton devices for overground ambulation recovery in acquired brain injury-A review. Front Neurorobot. 2023 May 25;17:1014616. doi: 10.3389/fnbot.2023.1014616. eCollection 2023.
- Background: PubMed 33975555Homayuni A, Abedini S, Hosseini Z, Etemadifar M, Ghanbarnejad A. Explaining the facilitators of quality of life in patients with multiple sclerosis: a qualitative study. BMC Neurol. 2021 May 11;21(1):193. doi: 10.1186/s12883-021-02213-9.
- Background: PubMed 33257490Gil-Gonzalez I, Martin-Rodriguez A, Conrad R, Perez-San-Gregorio MA. Quality of life in adults with multiple sclerosis: a systematic review. BMJ Open. 2020 Nov 30;10(11):e041249. doi: 10.1136/bmjopen-2020-041249.
- Derived from this study: PubMed 42717397Marcaccini K, Aleo A, Pozzi S, Sgambato G, Chiari L, Verrengia MG, Milano DC, Moscato S, Mellone S, Arcobelli VA, Sabattini L, Orlandi S. Interventional Feasibility Study Investigating Virtual Reality-Based Gait Assessment With Orthoses in People With Multiple Sclerosis: A Study Protocol. Clin Transl Sci. 2026 Sep;19(9):e70728. doi: 10.1111/cts.70728.
- Individual participant dataSharing planned: No
Related trials for Multiple Sclerosis
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
RecruitingPhase 3
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
Multiple Sclerosis
RecruitingPhase 2
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Loredana Sabattini principal investigator
IRCCS Istituto delle Scienze Neurologiche di Bologna - AUSL of Bologna
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing VR and walking brace-based gait rehabilitation in people with Multiple Sclerosis, run by Azienda Usl di Bologna at 2 sites in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kevin Marcaccini (+390514966403, kevin.marcaccini@ausl.bologna.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Score of the standardized tests and gait parameters (time frame: From T1 (day 2) to T2 (day 9)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07096700, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Mar 2026.